Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Kuan-Chieh Huang, Vilma Graupner, Shawn W. Sun, Tien Hoang, Helen Jessop, Mark L. McCleland, Marcus Ballinger, Alan Sandler, Mark A. Socinski

Journal of Thoracic Oncology, 2020

Rocky Mountain Cancer Centers, Texas Oncology, Azienda Unità Sanitaria Locale Della Romagna, Sumy State University, Moscow City Oncology Hospital №62, Universidad de Las Palmas de Gran Canaria, Hospital Universitario Insular de Gran Canaria, Sarah Cannon, Florida Cancer Specialists & Research Institute, National University Hospital, William Osler Health System, Shikoku Cancer Center, Roche (Switzerland), Roche (United Kingdom), Florida Hospital Cancer Institute

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with Journal of Thoracic Oncology. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

596

Citations

View on Google Scholar

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

Abstract

Journal Details

Join JournalsHub

Welcome Back